These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24840521)

  • 1. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
    Vormoor B; Curtin NJ
    Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.
    Brenner JC; Feng FY; Han S; Patel S; Goyal SV; Bou-Maroun LM; Liu M; Lonigro R; Prensner JR; Tomlins SA; Chinnaiyan AM
    Cancer Res; 2012 Apr; 72(7):1608-13. PubMed ID: 22287547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
    van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
    Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.
    Lee HJ; Yoon C; Schmidt B; Park DJ; Zhang AY; Erkizan HV; Toretsky JA; Kirsch DG; Yoon SS
    Mol Cancer Ther; 2013 Nov; 12(11):2591-600. PubMed ID: 23966622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ewing's sarcoma: overcoming the therapeutic plateau.
    Subbiah V; Kurzrock R
    Discov Med; 2012 Jun; 13(73):405-15. PubMed ID: 22742646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
    Choy E; Butrynski JE; Harmon DC; Morgan JA; George S; Wagner AJ; D'Adamo D; Cote GM; Flamand Y; Benes CH; Haber DA; Baselga JM; Demetri GD
    BMC Cancer; 2014 Nov; 14():813. PubMed ID: 25374341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
    Heisey DAR; Lochmann TL; Floros KV; Coon CM; Powell KM; Jacob S; Calbert ML; Ghotra MS; Stein GT; Maves YK; Smith SC; Benes CH; Leverson JD; Souers AJ; Boikos SA; Faber AC
    Clin Cancer Res; 2019 Mar; 25(5):1664-1675. PubMed ID: 30348635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors?
    Mangoni M; Sottili M; Salvatore G; Campanacci D; Scoccianti G; Beltrami G; Delli Paoli C; Dominici L; Maragna V; Olmetto E; Meattini I; Desideri I; Bonomo P; Greto D; Livi L
    Radiol Med; 2019 Apr; 124(4):282-289. PubMed ID: 29582320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects and challenges for the development of new therapies for Ewing sarcoma.
    Grohar PJ; Helman LJ
    Pharmacol Ther; 2013 Feb; 137(2):216-24. PubMed ID: 23085431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New strategies in ewing sarcoma: lost in translation?
    Arnaldez FI; Helman LJ
    Clin Cancer Res; 2014 Jun; 20(12):3050-6. PubMed ID: 24756371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP inhibitors for anticancer therapy.
    Curtin N
    Biochem Soc Trans; 2014 Feb; 42(1):82-8. PubMed ID: 24450632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
    Chugh R; Ballman KV; Helman LJ; Patel S; Whelan JS; Widemann B; Lu Y; Hawkins DS; Mascarenhas L; Glod JW; Ji J; Zhang Y; Reinke D; Strauss SJ
    Cancer; 2021 Apr; 127(8):1301-1310. PubMed ID: 33289920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
    Gill SJ; Travers J; Pshenichnaya I; Kogera FA; Barthorpe S; Mironenko T; Richardson L; Benes CH; Stratton MR; McDermott U; Jackson SP; Garnett MJ
    PLoS One; 2015; 10(10):e0140988. PubMed ID: 26505995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
    Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-Ribose) Polymerase-1 Inhibitors Drug Discovery, Design, and Development as Anticancer Agents from Past to Present: A Mini-Review.
    AlGhamdi A; AlMubayedh H
    Mini Rev Med Chem; 2022; 22(12):1597-1606. PubMed ID: 34587882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
    Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
    J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting poly(ADP-ribose) polymerase activity for cancer therapy.
    Mégnin-Chanet F; Bollet MA; Hall J
    Cell Mol Life Sci; 2010 Nov; 67(21):3649-62. PubMed ID: 20725763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
    Ordóñez JL; Amaral AT; Carcaboso AM; Herrero-Martín D; del Carmen García-Macías M; Sevillano V; Alonso D; Pascual-Pasto G; San-Segundo L; Vila-Ubach M; Rodrigues T; Fraile S; Teodosio C; Mayo-Iscar A; Aracil M; Galmarini CM; Tirado OM; Mora J; de Álava E
    Oncotarget; 2015 Aug; 6(22):18875-90. PubMed ID: 26056084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the DNA repair pathway in Ewing sarcoma.
    Stewart E; Goshorn R; Bradley C; Griffiths LM; Benavente C; Twarog NR; Miller GM; Caufield W; Freeman BB; Bahrami A; Pappo A; Wu J; Loh A; Karlström Å; Calabrese C; Gordon B; Tsurkan L; Hatfield MJ; Potter PM; Snyder SE; Thiagarajan S; Shirinifard A; Sablauer A; Shelat AA; Dyer MA
    Cell Rep; 2014 Nov; 9(3):829-41. PubMed ID: 25437539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.